Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated:  12/31/1969
Novartis Investigational Site
mi
from
Springfield, IL
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated: 12/31/1969
Novartis Investigational Site
mi
from
Springfield, IL
Click here to add this to my saved trials
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Williamsburg, MI
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Williamsburg, MI
Click here to add this to my saved trials
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Lincoln, NE
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Lincoln, NE
Click here to add this to my saved trials
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Omaha, NE
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Omaha, NE
Click here to add this to my saved trials
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Las Vegas, NV
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Toms River, NJ
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Toms River, NJ
Click here to add this to my saved trials
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated:  12/31/1969
Novartis
mi
from
New York, NY
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated: 12/31/1969
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Rochester, NY
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Rochester, NY
Click here to add this to my saved trials
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Slingerlands, NY
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Slingerlands, NY
Click here to add this to my saved trials
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Charlotte, NC
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Cincinnati, OH
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Cleveland, OH
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
West Mifflin, PA
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
West Mifflin, PA
Click here to add this to my saved trials
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Rapid City, SD
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Rapid City, SD
Click here to add this to my saved trials
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
mi
from
Kingsport, TN
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
mi
from
Kingsport, TN
Click here to add this to my saved trials
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Nashville, TN
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Nashville, TN
Click here to add this to my saved trials
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated:  12/31/1969
Novartis
mi
from
San Antonio, TX
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab
Status: Enrolling
Updated: 12/31/1969
Novartis
mi
from
San Antonio, TX
Click here to add this to my saved trials
The Impact of Soft Contact Lens Attributes on Symptoms Associated With Digital Eye Strain in Symptomatic Soft Contact Lens Wearers
The Impact of Soft Contact Lens Attributes on Symptoms Associated With Digital Eye Strain in Symptomatic Soft Contact Lens Wearers
Status: Enrolling
Updated:  12/31/1969
Indiana University Clinical Optics Research Lab
mi
from
Bloomington, IN
The Impact of Soft Contact Lens Attributes on Symptoms Associated With Digital Eye Strain in Symptomatic Soft Contact Lens Wearers
The Impact of Soft Contact Lens Attributes on Symptoms Associated With Digital Eye Strain in Symptomatic Soft Contact Lens Wearers
Status: Enrolling
Updated: 12/31/1969
Indiana University Clinical Optics Research Lab
mi
from
Bloomington, IN
Click here to add this to my saved trials
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Mixed Astigmatism
A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of Naturally Occuring Mixed Astigmatism Up To 6.0 D
Status: Enrolling
Updated:  12/31/1969
US Navy Refractive Surgery Center
mi
from
San Diego, CA
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Mixed Astigmatism
A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of Naturally Occuring Mixed Astigmatism Up To 6.0 D
Status: Enrolling
Updated: 12/31/1969
US Navy Refractive Surgery Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Mixed Astigmatism
A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of Naturally Occuring Mixed Astigmatism Up To 6.0 D
Status: Enrolling
Updated:  12/31/1969
Dishler Laser Institute
mi
from
Greenwood Village, CO
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Mixed Astigmatism
A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of Naturally Occuring Mixed Astigmatism Up To 6.0 D
Status: Enrolling
Updated: 12/31/1969
Dishler Laser Institute
mi
from
Greenwood Village, CO
Click here to add this to my saved trials
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Mixed Astigmatism
A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of Naturally Occuring Mixed Astigmatism Up To 6.0 D
Status: Enrolling
Updated:  12/31/1969
Discover Vision Centers
mi
from
Kansas City, MO
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Mixed Astigmatism
A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of Naturally Occuring Mixed Astigmatism Up To 6.0 D
Status: Enrolling
Updated: 12/31/1969
Discover Vision Centers
mi
from
Kansas City, MO
Click here to add this to my saved trials
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Mixed Astigmatism
A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of Naturally Occuring Mixed Astigmatism Up To 6.0 D
Status: Enrolling
Updated:  12/31/1969
Fine, Hoffman & Packer
mi
from
Eugene, OR
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Mixed Astigmatism
A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of Naturally Occuring Mixed Astigmatism Up To 6.0 D
Status: Enrolling
Updated: 12/31/1969
Fine, Hoffman & Packer
mi
from
Eugene, OR
Click here to add this to my saved trials
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Mixed Astigmatism
A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of Naturally Occuring Mixed Astigmatism Up To 6.0 D
Status: Enrolling
Updated:  12/31/1969
Davis Duehr Dean Eye Clinic
mi
from
Madison, WI
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Mixed Astigmatism
A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of Naturally Occuring Mixed Astigmatism Up To 6.0 D
Status: Enrolling
Updated: 12/31/1969
Davis Duehr Dean Eye Clinic
mi
from
Madison, WI
Click here to add this to my saved trials
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Moderate to High Myopia
A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of > -7.00 D to -12.00 D Of Myopia With Up To -6.00 D Of Astigmatism, and Maximum MRSE of ≤ -12.00 D
Status: Enrolling
Updated:  12/31/1969
US Navy Refractive Surgery Center
mi
from
San Diego, CA
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Moderate to High Myopia
A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of > -7.00 D to -12.00 D Of Myopia With Up To -6.00 D Of Astigmatism, and Maximum MRSE of ≤ -12.00 D
Status: Enrolling
Updated: 12/31/1969
US Navy Refractive Surgery Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Moderate to High Myopia
A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of > -7.00 D to -12.00 D Of Myopia With Up To -6.00 D Of Astigmatism, and Maximum MRSE of ≤ -12.00 D
Status: Enrolling
Updated:  12/31/1969
Dishler Laser Institute
mi
from
Greenwood Village, CO
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Moderate to High Myopia
A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of > -7.00 D to -12.00 D Of Myopia With Up To -6.00 D Of Astigmatism, and Maximum MRSE of ≤ -12.00 D
Status: Enrolling
Updated: 12/31/1969
Dishler Laser Institute
mi
from
Greenwood Village, CO
Click here to add this to my saved trials
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Moderate to High Myopia
A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of > -7.00 D to -12.00 D Of Myopia With Up To -6.00 D Of Astigmatism, and Maximum MRSE of ≤ -12.00 D
Status: Enrolling
Updated:  12/31/1969
Discover Vision Centers
mi
from
Kansas City, MO
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Moderate to High Myopia
A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of > -7.00 D to -12.00 D Of Myopia With Up To -6.00 D Of Astigmatism, and Maximum MRSE of ≤ -12.00 D
Status: Enrolling
Updated: 12/31/1969
Discover Vision Centers
mi
from
Kansas City, MO
Click here to add this to my saved trials
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Moderate to High Myopia
A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of > -7.00 D to -12.00 D Of Myopia With Up To -6.00 D Of Astigmatism, and Maximum MRSE of ≤ -12.00 D
Status: Enrolling
Updated:  12/31/1969
Fine, Hoffman & Packer
mi
from
Eugene, OR
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Moderate to High Myopia
A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of > -7.00 D to -12.00 D Of Myopia With Up To -6.00 D Of Astigmatism, and Maximum MRSE of ≤ -12.00 D
Status: Enrolling
Updated: 12/31/1969
Fine, Hoffman & Packer
mi
from
Eugene, OR
Click here to add this to my saved trials
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Moderate to High Myopia
A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of > -7.00 D to -12.00 D Of Myopia With Up To -6.00 D Of Astigmatism, and Maximum MRSE of ≤ -12.00 D
Status: Enrolling
Updated:  12/31/1969
Davis Duehr Dean Eye Clinic
mi
from
Madison, WI
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Moderate to High Myopia
A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of > -7.00 D to -12.00 D Of Myopia With Up To -6.00 D Of Astigmatism, and Maximum MRSE of ≤ -12.00 D
Status: Enrolling
Updated: 12/31/1969
Davis Duehr Dean Eye Clinic
mi
from
Madison, WI
Click here to add this to my saved trials
Clinical Evaluation of Approved and Investigational Contact Lenses Using New UV Additive
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Jacksonville, FL
Clinical Evaluation of Approved and Investigational Contact Lenses Using New UV Additive
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Clinical Evaluation of Approved and Investigational Contact Lenses Using New UV Additive
Status: Enrolling
Updated:  12/31/1969
mi
from
Longwood, FL
Clinical Evaluation of Approved and Investigational Contact Lenses Using New UV Additive
Status: Enrolling
Updated: 12/31/1969
mi
from
Longwood, FL
Click here to add this to my saved trials
Clinical Evaluation of Approved and Investigational Contact Lenses Using New UV Additive
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Sarasota, FL
Clinical Evaluation of Approved and Investigational Contact Lenses Using New UV Additive
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sarasota, FL
Click here to add this to my saved trials
Clinical Evaluation of Approved and Investigational Contact Lenses Using New UV Additive
Status: Enrolling
Updated:  12/31/1969
mi
from
Closter, NJ
Clinical Evaluation of Approved and Investigational Contact Lenses Using New UV Additive
Status: Enrolling
Updated: 12/31/1969
mi
from
Closter, NJ
Click here to add this to my saved trials
Clinical Evaluation of Approved and Investigational Contact Lenses Using New UV Additive
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Vestal, NY
Clinical Evaluation of Approved and Investigational Contact Lenses Using New UV Additive
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Vestal, NY
Click here to add this to my saved trials
Clinical Evaluation of Approved and Investigational Contact Lenses Using New UV Additive
Status: Enrolling
Updated:  12/31/1969
mi
from
Pickens, SC
Clinical Evaluation of Approved and Investigational Contact Lenses Using New UV Additive
Status: Enrolling
Updated: 12/31/1969
mi
from
Pickens, SC
Click here to add this to my saved trials
Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment
Prospective, Single-Arm Clinical Trial to Evaluate Acute Dry Eye Symptom Relief Assessed During Exposure to a Controlled Adverse Environment (CAE®) Following a 45 Day Period With Application of TrueTear™
Status: Enrolling
Updated:  12/31/1969
Andover Eye Associates
mi
from
Andover, MA
Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment
Prospective, Single-Arm Clinical Trial to Evaluate Acute Dry Eye Symptom Relief Assessed During Exposure to a Controlled Adverse Environment (CAE®) Following a 45 Day Period With Application of TrueTear™
Status: Enrolling
Updated: 12/31/1969
Andover Eye Associates
mi
from
Andover, MA
Click here to add this to my saved trials
Side Effects of Atropine (SEA) Study
Side Effects of Atropine (SEA) Study
Status: Enrolling
Updated:  12/31/1969
The Ohio State University College of Optometry
mi
from
Columbus, OH
Side Effects of Atropine (SEA) Study
Side Effects of Atropine (SEA) Study
Status: Enrolling
Updated: 12/31/1969
The Ohio State University College of Optometry
mi
from
Columbus, OH
Click here to add this to my saved trials
Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
Status: Enrolling
Updated:  12/31/1969
The Berman Center for Clinical Research
mi
from
Minneapolis, MN
Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
Status: Enrolling
Updated: 12/31/1969
The Berman Center for Clinical Research
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
Status: Enrolling
Updated:  12/31/1969
Columbia University
mi
from
New York, NY
Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
Status: Enrolling
Updated: 12/31/1969
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
Status: Enrolling
Updated:  12/31/1969
Case Western Reserve Univ
mi
from
Cleveland, OH
Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
Status: Enrolling
Updated: 12/31/1969
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
Status: Enrolling
Updated:  12/31/1969
Veterans Affairs
mi
from
Memphis, TN
Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
Status: Enrolling
Updated: 12/31/1969
Veterans Affairs
mi
from
Memphis, TN
Click here to add this to my saved trials
Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
Status: Enrolling
Updated:  12/31/1969
Univ of Washington
mi
from
Seattle, WA
Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
Status: Enrolling
Updated: 12/31/1969
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
Status: Enrolling
Updated:  12/31/1969
McMaster University
mi
from
Hamilton,
Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
Status: Enrolling
Updated: 12/31/1969
McMaster University
mi
from
Hamilton,
Click here to add this to my saved trials
KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children
Safety and Efficacy of KPI-121 1% Ophthalmic Suspension Versus Prednisolone Acetate Ophthalmic Suspension 1% for the Treatment of Inflammation Following Cataract Surgery in Children 0 to 3 Years of Age
Status: Enrolling
Updated:  12/31/1969
Pediatric Ophthalmology of Erie
mi
from
Erie, PA
KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children
Safety and Efficacy of KPI-121 1% Ophthalmic Suspension Versus Prednisolone Acetate Ophthalmic Suspension 1% for the Treatment of Inflammation Following Cataract Surgery in Children 0 to 3 Years of Age
Status: Enrolling
Updated: 12/31/1969
Pediatric Ophthalmology of Erie
mi
from
Erie, PA
Click here to add this to my saved trials
KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children
Safety and Efficacy of KPI-121 1% Ophthalmic Suspension Versus Prednisolone Acetate Ophthalmic Suspension 1% for the Treatment of Inflammation Following Cataract Surgery in Children 0 to 3 Years of Age
Status: Enrolling
Updated:  12/31/1969
Byers Eye Institute at Stanford University
mi
from
Palo Alto, CA
KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children
Safety and Efficacy of KPI-121 1% Ophthalmic Suspension Versus Prednisolone Acetate Ophthalmic Suspension 1% for the Treatment of Inflammation Following Cataract Surgery in Children 0 to 3 Years of Age
Status: Enrolling
Updated: 12/31/1969
Byers Eye Institute at Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children
Safety and Efficacy of KPI-121 1% Ophthalmic Suspension Versus Prednisolone Acetate Ophthalmic Suspension 1% for the Treatment of Inflammation Following Cataract Surgery in Children 0 to 3 Years of Age
Status: Enrolling
Updated:  12/31/1969
Children's Eye Care, PC
mi
from
Detroit, MI
KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children
Safety and Efficacy of KPI-121 1% Ophthalmic Suspension Versus Prednisolone Acetate Ophthalmic Suspension 1% for the Treatment of Inflammation Following Cataract Surgery in Children 0 to 3 Years of Age
Status: Enrolling
Updated: 12/31/1969
Children's Eye Care, PC
mi
from
Detroit, MI
Click here to add this to my saved trials
KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children
Safety and Efficacy of KPI-121 1% Ophthalmic Suspension Versus Prednisolone Acetate Ophthalmic Suspension 1% for the Treatment of Inflammation Following Cataract Surgery in Children 0 to 3 Years of Age
Status: Enrolling
Updated:  12/31/1969
Houston Eye Associates
mi
from
The Woodlands, TX
KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children
Safety and Efficacy of KPI-121 1% Ophthalmic Suspension Versus Prednisolone Acetate Ophthalmic Suspension 1% for the Treatment of Inflammation Following Cataract Surgery in Children 0 to 3 Years of Age
Status: Enrolling
Updated: 12/31/1969
Houston Eye Associates
mi
from
The Woodlands, TX
Click here to add this to my saved trials
Contact Lens Insertion and Removal in a Senior Subject Demographic
Contact Lens Insertion and Removal in a Senior Subject Demographic
Status: Enrolling
Updated:  12/31/1969
VRC East
mi
from
Jacksonville, FL
Contact Lens Insertion and Removal in a Senior Subject Demographic
Contact Lens Insertion and Removal in a Senior Subject Demographic
Status: Enrolling
Updated: 12/31/1969
VRC East
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetics, and Pharmacodynamics of AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease (DED)
A Multicenter, Vehicle-controlled, Randomized Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetics, and Pharmacodynamics of AXR-159 Ophthalmic Solution 3 mg/mL, 30 mg/mL, and 50 mg/mL in Patients With Dry Eye Disease (DED)
Status: Enrolling
Updated:  12/31/1969
Andover Eye Associates
mi
from
Andover, MA
A Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetics, and Pharmacodynamics of AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease (DED)
A Multicenter, Vehicle-controlled, Randomized Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetics, and Pharmacodynamics of AXR-159 Ophthalmic Solution 3 mg/mL, 30 mg/mL, and 50 mg/mL in Patients With Dry Eye Disease (DED)
Status: Enrolling
Updated: 12/31/1969
Andover Eye Associates
mi
from
Andover, MA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetics, and Pharmacodynamics of AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease (DED)
A Multicenter, Vehicle-controlled, Randomized Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetics, and Pharmacodynamics of AXR-159 Ophthalmic Solution 3 mg/mL, 30 mg/mL, and 50 mg/mL in Patients With Dry Eye Disease (DED)
Status: Enrolling
Updated:  12/31/1969
Andover Eye Associates
mi
from
Raynham, MA
A Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetics, and Pharmacodynamics of AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease (DED)
A Multicenter, Vehicle-controlled, Randomized Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetics, and Pharmacodynamics of AXR-159 Ophthalmic Solution 3 mg/mL, 30 mg/mL, and 50 mg/mL in Patients With Dry Eye Disease (DED)
Status: Enrolling
Updated: 12/31/1969
Andover Eye Associates
mi
from
Raynham, MA
Click here to add this to my saved trials